In a period of less than one year, the authors observed three young patients in whom primary gastrointestinal carcinomas developed. Two of them had acquired immune deficiency syndrome and the other one was human immunodeficiency virus (HIV) antibody-positive drug abuser. This report is intended to alert the medical profession to gastrointestinal malignancy as a possible complication of HIV infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ajcp/91.4.458 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Study on the Technical Parameters for Estimating HIV-1 Incidence by Using a Recombinant Antigen-based Capture Enzyme Immunoassay - China.
China CDC Wkly
November 2024
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Introduction: A novel recombinant antigen-based capture enzyme immunoassay (RAg-CEIA) was optimized and used to determine technical parameters for estimating human immunodeficiency virus type 1 (HIV-1) incidence in China.
Methods: We employed orthogonal experimental design to optimize RAg-CEIA by adjusting raw material dilution ratios. The assay was used to measure normalized optical density (ODn) values in 171 longitudinal plasma specimens from 51 HIV-1 seroconverting individuals, plotted against estimated days post-seroconversion.
Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014-2023).
Open Forum Infect Dis
December 2024
The Kirby Institute, University of New South Wales, Sydney, Australia.
Background: Approximately 10% of people with HIV in Australia had active hepatitis C virus (HCV) infection prior to availability of government-subsidized direct-acting antiviral (DAA) therapy in 2016. This analysis evaluated progress toward HCV elimination among people with HIV in Australia between 2014 and 2023.
Methods: The CEASE cohort study enrolled adults with HIV with past or current HCV infection (anti-HCV antibody positive) from 14 primary and tertiary clinics.
Clinical and chest CT manifestations of Talaromycosis marneffei: a retrospective study comparing anti-IFN-γ autoantibodies-positive and HIV-positive cases.
BMC Infect Dis
November 2024
Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China.
Background: To explore the clinical and chest CT features of Talaromycosis marneffei (TSM), and to compare the differences between anti‑IFN‑γ autoantibodies‑positive and HIV-positive cases.
Methods: Clinical data and chest CT images of 54 HIV-negative patients with Talaromyces marneffei (TM) infection and positive anti-interferon-γ (anti-IFN-γ) autoantibody were retrospectively analyzed. Ninety-three HIV-positive patients with TM infection during the same period were included as controls.
Routine screening for antibodies to human immunodeficiency virus in the U.S. Armed Forces, active and reserve components, January 2019-June 2024.
MSMR
October 2024
Defense Health Agency, U.S. Department of Defense.
Summaries of HIV seropositivity for members of the U.S. military have been published with MSMR since 1995.
View Article and Find Full Text PDFFrom Diagnosis to Dialysis: Managing Primary Membranous Nephropathy in a Patient Living With Human Immunodeficiency Virus (HIV).
Cureus
August 2024
Nephrology, Athens Kidney Center, Oconee Medical Group, Athens, USA.
Article Synopsis
- Despite receiving treatment, including rituximab, and being diagnosed with anti-PLA2R antibody-positive MN, the patient faced disease progression due to non-adherence to therapy, culminating in end-stage renal disease (ESRD) and hospitalization for heart failure.
- The case highlights the difficulties in managing MN in patients with HIV and emphasizes the critical need for consistent treatment adherence and personalized management strategies to improve patient outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!